ID: ALA1802401

Max Phase: Preclinical

Molecular Formula: C12H9N5O2

Molecular Weight: 255.24

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1nccc(-c2c[nH]c3c([N+](=O)[O-])cccc23)n1

Standard InChI:  InChI=1S/C12H9N5O2/c13-12-14-5-4-9(16-12)8-6-15-11-7(8)2-1-3-10(11)17(18)19/h1-6,15H,(H2,13,14,16)

Standard InChI Key:  SYRGMMJIEWOFNF-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 255.24

Molecular Weight (Monoisotopic): 255.0756

AlogP: 2.12

#Rotatable Bonds: 2

Polar Surface Area: 110.73

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.43

CX Basic pKa: 3.57

CX LogP: 1.97

CX LogD: 1.97

Aromatic Rings: 3

Heavy Atoms: 19

QED Weighted: 0.54

Np Likeness Score: -0.90

References

1. Giraud F, Alves G, Debiton E, Nauton L, Théry V, Durieu E, Ferandin Y, Lozach O, Meijer L, Anizon F, Pereira E, Moreau P..  (2011)  Synthesis, protein kinase inhibitory potencies, and in vitro antiproliferative activities of meridianin derivatives.,  54  (13): [PMID:21623630] [10.1021/jm200464w]

2. Shaw SJ, Goff DA, Lin N, Singh R, Li W, McLaughlin J, Baltgalvis KA, Payan DG, Kinsella TM..  (2017)  Developing DYRK inhibitors derived from the meridianins as a means of increasing levels of NFAT in the nucleus.,  27  (11): [PMID:28408219] [10.1016/j.bmcl.2017.03.037]

Source

Source(1):

• Scientific Literature